Abstract
Background: Access to medical care vary across the world and is related to different health systems with an impact in recurrence.Objective: To evaluate disparities in breast cancer(BC) diagnosis and treatment between public and private services in southwest Brazil and at two public safety net hospitals in Houston, Texas.Methods: Women diagnosed with BC stages I-III between 2009 to 2011, and treated at the four hospitals in Brazil and two health centers in US were included. All statistical analyses were performed in R studio software, and p<0.05 was considered significant.Results: 1245 women were included: 967 from public health system (PHS) (20.3% from Houston, Texas) and 274 from private system(PS). Recurrence rate was higher in PHS (14.6% vs. 2.6%, p<0.001)
Characteristics | Public (%), n=967 | Private (%), n=274 | p |
Discovery of BC | |||
By patient | 530 (54.8) | 92 (33.5) | |
Routine exam | 87 (9) | 109 (39.8) | |
Screening mammography | 270 (27.9) | 23 (8.4) | |
Other | 80 (8.3) | 50 (18.3) | <0.001 |
Initial treatment | |||
Surgery | 687 (71) | 241 (88) | |
Neo-adjuvant chemotherapy | 224 (23.2) | 27 (9.8) | |
Neo-adjuvant hormone therapy | 23 (2.3) | 27 (9.8) | |
Not available | 33 (3.4) | 3 (1.1) | <0.001 |
Clinical Stage | |||
I | 293 (30.3) | 113 (41.2) | |
II | 342 (35.4) | 52 (19) | |
III | 271 (28) | 15 (5.5) | |
Unknown | 61 (6.3) | 94 (34.3) | <0.001 |
Subtype | |||
HR+/HER2 - | 561 (58) | 192 (70.1) | |
HR-/HER2+ | 108 (11.1) | 29 (10.6) | |
HR-/HER2+ | 76 (7.9) | 14 (5.1) | |
Triple negative | 149 (15.4) | 28 (10.2) | |
Unknown | 73 (7.6) | 11 (4) | 0.012 |
Symptomatic at Diagnosis | |||
Yes | 591 (61.1) | 100 (36.5) | |
No | 306 (31.6) | 97 (35.4) | |
Unknown | 70 (7.2) | 77 (28.1) | <0.001 |
Recurence | n=772 | n=146 | |
No | 719 (74.4) | 193 (70.4) | |
Yes | 142 (14.6) | 7 (2.6) | |
Unknown | 106 (11) | 74 (27) | <0.001 |
Characteristics | Public (%), n=967 | Private (%), n=274 | p |
Discovery of BC | |||
By patient | 530 (54.8) | 92 (33.5) | |
Routine exam | 87 (9) | 109 (39.8) | |
Screening mammography | 270 (27.9) | 23 (8.4) | |
Other | 80 (8.3) | 50 (18.3) | <0.001 |
Initial treatment | |||
Surgery | 687 (71) | 241 (88) | |
Neo-adjuvant chemotherapy | 224 (23.2) | 27 (9.8) | |
Neo-adjuvant hormone therapy | 23 (2.3) | 27 (9.8) | |
Not available | 33 (3.4) | 3 (1.1) | <0.001 |
Clinical Stage | |||
I | 293 (30.3) | 113 (41.2) | |
II | 342 (35.4) | 52 (19) | |
III | 271 (28) | 15 (5.5) | |
Unknown | 61 (6.3) | 94 (34.3) | <0.001 |
Subtype | |||
HR+/HER2 - | 561 (58) | 192 (70.1) | |
HR-/HER2+ | 108 (11.1) | 29 (10.6) | |
HR-/HER2+ | 76 (7.9) | 14 (5.1) | |
Triple negative | 149 (15.4) | 28 (10.2) | |
Unknown | 73 (7.6) | 11 (4) | 0.012 |
Symptomatic at Diagnosis | |||
Yes | 591 (61.1) | 100 (36.5) | |
No | 306 (31.6) | 97 (35.4) | |
Unknown | 70 (7.2) | 77 (28.1) | <0.001 |
Recurence | n=772 | n=146 | |
No | 719 (74.4) | 193 (70.4) | |
Yes | 142 (14.6) | 7 (2.6) | |
Unknown | 106 (11) | 74 (27) | <0.001 |
. Considering the interval in weeks: symptoms to diagnosis, diagnosis to first treatment (either surgery or neoadjuvant chemotherapy), diagnosis to first systemic treatment, diagnosis to surgical treatment and diagnosis to radiotherapy were longer in public patients (24.1 vs. 8.7; 11.1 vs. 3.5; 18.6 vs. 9.8; 16.9 vs. 5.6; 51.4 vs. 26.1; p<0.001).
Public | Private | p | |
Symptoms to diagnosis | |||
Number of patients | 575 | 146 | |
Time (weeks) | 24.1 (0.4-104.9) | 8.7 (0.0-43.7) | <0.001 |
Diagnosis to first treatment | |||
Number of patients | 663 | 180 | |
Time (weeks) | 11.1 (2.0-31.5) | 3.5 (0.0-11.0) | <0.001 |
Diagnosis to first systemic treatment | |||
Number of patients | 526 | 106 | |
Time (weeks) | 18.6 (2.6-44.7) | 9.8 (1.9-29.3) | <0.001 |
Diagnosis to surgical treatment | |||
Number of patients | 657 | 178 | |
Time (weeks) | 16.9 (3.4-45.6) | 5.6 (0.0-32.9) | <0.001 |
Diagnosis to radiotherapy | |||
Number of patients | 465 | 127 | |
Time (weeks) | 51.4 (18.7-88.4) | 26.1 (5.6-66.4) | <0.001 |
Public | Private | p | |
Symptoms to diagnosis | |||
Number of patients | 575 | 146 | |
Time (weeks) | 24.1 (0.4-104.9) | 8.7 (0.0-43.7) | <0.001 |
Diagnosis to first treatment | |||
Number of patients | 663 | 180 | |
Time (weeks) | 11.1 (2.0-31.5) | 3.5 (0.0-11.0) | <0.001 |
Diagnosis to first systemic treatment | |||
Number of patients | 526 | 106 | |
Time (weeks) | 18.6 (2.6-44.7) | 9.8 (1.9-29.3) | <0.001 |
Diagnosis to surgical treatment | |||
Number of patients | 657 | 178 | |
Time (weeks) | 16.9 (3.4-45.6) | 5.6 (0.0-32.9) | <0.001 |
Diagnosis to radiotherapy | |||
Number of patients | 465 | 127 | |
Time (weeks) | 51.4 (18.7-88.4) | 26.1 (5.6-66.4) | <0.001 |
In multivariate analysis, PHS (HR 1.72; 95% CI 1.34-1.88; p adj=0.003), presence of symptoms (HR 2.29; 95% CI 1.39-3.78; p adj=0.001), clinical stage III (HR 1.62; 95% CI 1.35-1.93; p adj<0.001), and triple negativity and HER2neu positivity (1.18; 95% CI 1.03-1.35; p adj=0.021) were all associated with a higher recurrence rate.Conclusions: There were significant disparities between PHS and PS. Women in the PHS presented higher rates of recurrence, advanced clinical stages at diagnosis, symptoms and more aggressive subtypes by IHC. additionally, the interval between symptoms to diagnosis and diagnosis to treatments was longer in PHS.
Citation Format: NematiShafaee M, Natal RA, Ramalho S, Dória MT, Conz L, Cabello V, Pavanello M, Mano MS, Linck RDM, Batista LS, Pedro EP, Bines J, de Paula BH, Zucca-Matthes G, Bondy ML, Ellis MJ, Podany E, Debord L, Makawita S, Stewart K, Cabello C. Impact of delay in breast cancer diagnosis and treatment according to health insurance status in southwest Brazil and Houston, Texas [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-10-15.